# breast cancer - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: breast tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: 2eef237c25053f55d87c73e963368cae88b5c698447f11e7e98ebc594d62e5bb
- Response HTTP status: 200
- Prompt tokens: 3922
- Completion tokens: 13047
- Reasoning tokens: 
- Total tokens: 16969
- API requests reported: 
- Elapsed seconds: 128.526
- Final benchmark system: raw; file rank 2/5; original repeat 3; model vendor: DeepSeek

---
## Interpretation summary

In this breast cancer overall survival (OS) analysis, risk-associated genes (HR > 1) are strongly enriched for tumor-intrinsic proliferation and biosynthetic programs: cell-cycle progression, mitotic spindle control, DNA replication and repair, RNA translation/ribosome biogenesis, and metabolic reprogramming. Protective-associated genes (HR < 1) are enriched for immune-cell lineage markers, extracellular-matrix/stromal components, and differentiation-associated regulators. The most coherent interpretation is that aggressive tumor biology—especially high proliferative and biosynthetic capacity—is associated with worse survival, whereas a more favorable prognosis is associated with an active immune microenvironment and a more differentiated/stroma-rich tumor context.

This does not prove causation. The data are bulk-tissue expression associations, and both tumor-cell-intrinsic programs and tissue-composition effects can produce these signals.

---

## 1. Overall biological interpretation

The transcriptomic signature separates into two broad biological axes:

- **Poor-prognosis axis**: coordinated up-expression of genes involved in mitosis, DNA replication, nucleotide metabolism, ribosome biogenesis, mRNA translation, ubiquitin-proteasome activity, and lipid/glucose metabolism. This is consistent with rapidly proliferating, metabolically active tumor cells.
- **Favorable-prognosis axis**: coordinated expression of immune lineage markers, especially plasmacytoid/dendritic-cell and T/NK-cell markers, plus extracellular-matrix and adhesion molecules. This is consistent with immune-cell infiltration and a more differentiated or less aggressively proliferating tumor microenvironment.

The effect sizes are modest (HR approximately 0.79–1.26), but the FDR values are extremely low, and the gene-level consistency across coherent pathways strengthens the biological interpretation.

---

## 2. Core biological programs

### Program 1: Cell-cycle progression and mitotic control  
**Direction:** Risk-associated (HR > 1)  
**Supporting genes:** AURKA, TPX2, KIF20A, KIF4A, RACGAP1, CDC20, PTTG1, ZWINT, CENPO, NUSAP1, PRC1, CKAP2L, PKMYT1, CDCA5, UBE2C, CCNE2, TIMELESS  
**Best pathway annotation:** Hallmark G2M_CHECKPOINT; Reactome Cell Cycle/Mitotic; KEGG Cell Cycle  
**Interpretation:** Many of these genes encode mitotic kinases, spindle-assembly factors, APC/C regulators, kinetochore proteins, and cytokinesis components. Their coordinated expression strongly suggests an aggressive proliferation program.  
**Evidence strength:** Strong—supported by many independent genes, extremely low FDRs, and coherent pathway annotation.  
**Main limitation:** This signal may partly reflect overall proliferation rate rather than a specific therapeutic vulnerability.

### Program 2: RNA translation, ribosome biogenesis, and protein homeostasis  
**Direction:** Risk-associated (HR > 1)  
**Supporting genes:** LARP1, UTP23, YTHDF1, DDX41, STIP1, PSMD3, UBE2S, FAF2, ZFP91  
**Best pathway annotation:** Reactome Translation; Reactome Ribosome Biogenesis; Hallmark MTORC1_SIGNALING  
**Interpretation:** LARP1 is an mTOR-regulated RNA-binding protein that controls translation of ribosomal-protein mRNAs; UTP23 and DDX41 are involved in ribosome assembly; YTHDF1 promotes m6A-dependent translation; STIP1 participates in Hsp70/Hsp90 chaperone function; PSMD3 and UBE2S are linked to ubiquitin-proteasome turnover. Together these genes support increased protein production and proteostasis needed for tumor growth.  
**Evidence strength:** Moderate. The genes are biologically coherent, but some also overlap with cell-cycle or stress-response functions.  
**Main limitation:** This is a bulk-tissue signal; the precise cell type driving this program is not resolved.

### Program 3: Metabolic reprogramming—fatty acid oxidation and energy metabolism  
**Direction:** Risk-associated (HR > 1)  
**Supporting genes:** CPT1A, HACD3, GPI, ALG3, GSK3B, TRIB3, ATP2A2  
**Best pathway annotation:** Hallmark FATTY_ACID_METABOLISM; KEGG Fatty Acid Degradation; KEGG Glycolysis/Gluconeogenesis  
**Interpretation:** CPT1A is the rate-limiting enzyme for mitochondrial fatty-acid oxidation; HACD3 is involved in fatty-acid elongation; GPI is a glycolytic enzyme; ALG3 is involved in N-glycosylation. This pattern suggests metabolic adaptations supporting proliferation and membrane biosynthesis.  
**Evidence strength:** Moderate. The gene set is smaller than the cell-cycle set, and some genes such as GSK3B are multifunctional.  
**Main limitation:** Metabolic gene expression may be influenced by tumor hypoxia, stromal metabolism, or systemic metabolic state.

### Program 4: Immune-cell infiltration and antitumor immunity  
**Direction:** Protective-associated (HR < 1)  
**Supporting genes:** FCER1A, CD1C, CD1E, FLT3, JCHAIN, KLRB1, IL27RA, STAT5A, STAT5B  
**Best pathway annotation:** Reactome Adaptive Immune System; KEGG Antigen Processing and Presentation  
**Interpretation:** These genes are highly suggestive of immune-cell presence: FCER1A, CD1C, CD1E, and FLT3 are dendritic-cell/myeloid lineage markers; JCHAIN marks plasma cells/B cells; KLRB1 marks NK/T cells; IL27RA and STAT5A/B are involved in cytokine signaling. In breast cancer, immune infiltration is generally associated with a favorable prognosis.  
**Evidence strength:** Strong for a prognostic association, but it is likely a composition signal rather than a tumor-cell-intrinsic program.  
**Main limitation:** Bulk tissue cannot distinguish whether this protective signal is driven by immune-cell abundance or by tumor-cell expression of immune-related genes.

### Program 5: Stromal/extracellular-matrix composition and differentiation context  
**Direction:** Protective-associated (HR < 1)  
**Supporting genes:** COL14A1, MFAP4, OGN, OMD, LAMA2, DST, ADAMTS8, CLDN11, PCDH18, RELN, IGSF10, LRFN5, COL17A1, TP63, CBX7, CDKN2C, IGFBP6  
**Best pathway annotation:** Reactome Extracellular Matrix Organization; KEGG ECM-Receptor Interaction; Hallmark EPITHELIAL_MESENCHYMAL_TRANSITION with caution  
**Interpretation:** These genes encode extracellular-matrix proteins, cell-adhesion molecules, basement-membrane components, and differentiation-related transcription/chromatin regulators. Their favorable association may reflect a less invasive phenotype, a more differentiated tumor state, or a stromal microenvironment that does not support aggressive tumor growth.  
**Evidence strength:** Moderate. Many genes are coherent, but this program is particularly vulnerable to tumor-purity and cell-composition confounding.  
**Main limitation:** Some of these genes may simply mark normal stroma or normal epithelial contamination rather than biologically protective tumor features.

---

## 3. Key genes and interaction modules

The following modules are prioritized because they integrate multiple genes with consistent direction and biological coherence.

### Module 1: AURKA–TPX2–KIF20A–KIF4A–RACGAP1–PRC1  
- **Direction:** Risk-associated.  
- **Prognostic signal:** All show HR > 1; AURKA, TPX2, KIF20A, KIF4A, RACGAP1, PRC1 are significant at very low FDR.  
- **Biological role:** Mitotic spindle assembly, chromosome segregation, and cytokinesis.  
- **Gene-gene relationships:** AURKA–TPX2 is a direct physical/regulatory interaction; TPX2 binds and activates AURKA. KIF20A, KIF4A, RACGAP1, and PRC1 are best described as pathway co-members and co-expressed mitotic regulators, not necessarily direct physical partners.

### Module 2: CDC20–PTTG1–UBE2C–ZWINT–CENPO  
- **Direction:** Risk-associated.  
- **Prognostic signal:** All HR > 1; FDR < 1e-6 for each.  
- **Biological role:** APC/C ubiquitin-ligase activity, mitotic checkpoint, and sister-chromatid segregation.  
- **Gene-gene relationships:** CDC20 is a cofactor of the APC/C; UBE2C is an APC/C-associated E2 ubiquitin-conjugating enzyme; PTTG1 is an APC/C substrate. These are likely pathway-co-membership relationships, with some documented complex-level physical interactions, but the current dataset itself only supports co-expression and pathway co-membership.

### Module 3: CCNE2–TK1–FEN1–TIMELESS–UHRF1  
- **Direction:** Risk-associated.  
- **Prognostic signal:** HR > 1 for all; CCNE2, TK1, FEN1, TIMELESS, UHRF1 all reach very low FDR.  
- **Biological role:** G1/S progression, nucleotide biosynthesis, DNA replication, and DNA-replication stress response.  
- **Gene-gene relationships:** CCNE2/CDK2 activity promotes E2F-dependent transcription, which can co-regulate TK1, FEN1, TIMELESS, and UHRF1. This is best classified as a regulatory/co-expression relationship rather than direct physical interaction.

### Module 4: LARP1–YTHDF1–UTP23–DDX41–STIP1  
- **Direction:** Risk-associated.  
- **Prognostic signal:** HR > 1 for LARP1, YTHDF1, UTP23, DDX41, STIP1; all significant.  
- **Biological role:** mRNA translation, m6A-dependent translation, ribosome biogenesis, and chaperone-assisted protein folding.  
- **Gene-gene relationships:** These genes participate in overlapping but distinct protein-production pathways. LARP1 and YTHDF1 both regulate translation but via different mechanisms; UTP23 and DDX41 contribute to ribosome assembly; STIP1 is a chaperone cofactor. The relationship is best described as pathway co-membership/co-expression, not direct physical interaction.

### Module 5: CPT1A–HACD3–GPI–ALG3  
- **Direction:** Risk-associated.  
- **Prognostic signal:** HR > 1; all significant.  
- **Biological role:** Fatty-acid oxidation, fatty-acid elongation, glycolysis, and N-glycosylation.  
- **Gene-gene relationships:** Co-expressed metabolic enzymes belonging to overlapping metabolic programs; no direct physical interaction is implied.

### Module 6: FCER1A–CD1C–CD1E–FLT3–JCHAIN–KLRB1–IL27RA  
- **Direction:** Protective-associated.  
- **Prognostic signal:** HR < 1; all significant.  
- **Biological role:** Probable markers of dendritic cells, plasma cells, and NK/T cells; collectively indicate immune-cell infiltration.  
- **Gene-gene relationships:** These are likely co-expressed because they mark overlapping immune-cell populations. CD1C and CD1E are antigen-presenting molecules on dendritic cells; FCER1A is an Fc receptor; FLT3 is expressed on dendritic-cell progenitors; JCHAIN is a B/plasma-cell marker; KLRB1 is an NK/T-cell marker. This is co-expression/lineage co-membership, not direct physical interaction.

### Module 7: STAT5A–STAT5B  
- **Direction:** Protective-associated.  
- **Prognostic signal:** HR < 1 for both.  
- **Biological role:** Cytokine/JAK-STAT signaling; in breast cancer, STAT5 activity is often linked to differentiation and favorable outcome.  
- **Gene-gene relationships:** STAT5A and STAT5B are homologous transcription factors that can form homo- and heterodimers. The current dataset supports co-expression; the direct physical dimerization is known from external biochemical evidence, not from this analysis.

### Module 8: COL14A1–MFAP4–OGN–OMD–LAMA2–DST–ADAMTS8  
- **Direction:** Protective-associated.  
- **Prognostic signal:** HR < 1; all significant.  
- **Biological role:** Extracellular-matrix composition, basement-membrane/adhesion structures, and stromal differentiation.  
- **Gene-gene relationships:** These genes are mostly secreted ECM proteins or ECM-associated molecules. They may be co-expressed because they are produced by stromal fibroblasts or differentiated epithelial cells. The relationship is co-expression/pathway co-membership, not necessarily direct physical interaction.

---

## 4. Validation priorities

### Priority 1: Mitotic/cell-cycle dependency as a mechanistic driver  
- **Category:** Mechanistic hypothesis  
- **Why it deserves prioritization:** The cell-cycle/mitotic program is the strongest and most coherent risk-associated signal in the dataset.  
- **Current evidence:** AURKA, CDC20, TPX2, KIF20A, UBE2C, PTTG1, and related genes are all risk-associated with very low FDR.  
- **External support:** Mitotic kinases and APC/C components are established cancer-therapy targets; AURKA inhibitors already exist. However, drug existence alone does not prove therapeutic efficacy in breast cancer.  
- **Next step:** Genetic or pharmacological perturbation of AURKA, CDC20, or UBE2C in breast cancer models, with proliferation and survival endpoints.  
- **Evidence status:** Supported hypothesis, not established causality.

### Priority 2: Immune-cell composition as the basis of the protective signal  
- **Category:** Confounding or composition check  
- **Why it deserves prioritization:** The protective immune gene set may simply reflect immune-cell abundance in bulk tumor tissue, not tumor-cell biology.  
- **Current evidence:** FCER1A, CD1C, CD1E, FLT3, JCHAIN, KLRB1, and IL27RA are protective.  
- **External support:** Immune infiltration is a well-known favorable prognostic factor in breast cancer.  
- **Next step:** Perform immune deconvolution (CIBERSORTx, MCPcounter, xCell) on bulk RNA-seq, and validate cell-type localization with single-cell RNA-seq or multiplex immunohistochemistry.  
- **Evidence status:** Supported hypothesis.

### Priority 3: Multigene prognostic biomarker development  
- **Category:** Biomarker  
- **Why it deserves prioritization:** A combined proliferation/immune/stroma score could improve OS stratification beyond single genes.  
- **Current evidence:** The dataset provides many significant, directionally consistent genes, but no multivariate model or independent cohort validation.  
- **External support:** Proliferation and immune signatures are already clinically relevant in breast cancer.  
- **Next step:** Build and test a compact risk score in independent breast cancer cohorts with clinical stage, subtype, and treatment data, with multivariable adjustment.  
- **Evidence status:** Exploratory hypothesis.

### Priority 4: Translation/ribosome/proteostasis axis as a potential therapeutic target  
- **Category:** Therapeutic target  
- **Why it deserves prioritization:** This axis is distinct from classical proliferation pathways and may offer targetable dependencies.  
- **Current evidence:** LARP1, YTHDF1, UTP23, DDX41, and STIP1 are all risk-associated.  
- **External support:** LARP1 is a downstream effector of mTOR; YTHDF1 promotes translation of m6A-modified mRNAs in cancer; ribosome biogenesis is frequently upregulated in aggressive tumors.  
- **Next step:** Test loss-of-function effects of LARP1, YTHDF1, and STIP1 in breast cancer cell lines and organoids; evaluate mTOR or translation inhibitors in models with high expression of this program.  
- **Evidence status:** Exploratory hypothesis.

### Priority 5: Metabolic reprogramming, especially CPT1A/fatty-acid oxidation  
- **Category:** Mechanistic hypothesis / therapeutic target  
- **Why it deserves prioritization:** CPT1A is a druggable metabolic enzyme, and the risk association is biologically plausible in anabolic tumors.  
- **Current evidence:** CPT1A, HACD3, GPI, and ALG3 are risk-associated.  
- **External support:** Fatty-acid oxidation supports tumor growth in multiple cancer types, but CPT1 inhibitors have off-target effects and clinical efficacy is unproven.  
- **Next step:** Measure CPT1A expression and fatty-acid oxidation flux in breast cancer models; test genetic knockdown and metabolic inhibitors in appropriate contexts.  
- **Evidence status:** Exploratory hypothesis.

---

## 5. Evidence grounding

- **Direct statistical evidence from the input dataset:** HR, P value, and FDR for each gene. This is the only quantitative evidence supplied.
- **Pathway/ontology evidence:** Gene-to-pathway annotations from GO, Reactome, KEGG, and Hallmark are used to group genes into biological programs. These annotations are external and not derived from the input dataset.
- **Protein interaction/regulatory evidence:** Statements about AURKA–TPX2 binding, APC/C–CDC20–UBE2C relationships, and STAT5A/STAT5B dimerization come from published biochemical knowledge, not from the input data.
- **Disease-association evidence:** The interpretation that proliferation is unfavorable and immune infiltration is favorable in breast cancer is supported by extensive published literature, but independent cohort data were not provided here.
- **Expression/tissue-specific evidence:** The assignment of FCER1A, CD1C, CD1E, FLT3, JCHAIN, and KLRB1 as immune-lineage markers is based on known cell-type expression patterns.
- **Drug/therapeutic evidence:** Drug availability for AURKA, CPT1A, or mTOR components should not be interpreted as proof of therapeutic relevance in this specific dataset.

When multiple lines of evidence point to the same conclusion, they are not always fully independent. For example, the co-expression of AURKA, CDC20, and TPX2 in this dataset and their annotation to the same mitotic pathway are overlapping, not independent, types of evidence.

---

## 6. Limitations and alternative explanations

### 1. Bulk tissue and cell-composition effects
The data come from breast tumor tissue, not purified tumor cells. Protective immune and stromal genes may simply reflect higher leukocyte or stromal content, while risk genes may reflect higher tumor-cell content or proliferation. These possibilities cannot be separated from the current table alone.

### 2. Tumor purity
Low tumor purity can create spurious “protective” signals from normal breast epithelium, stroma, or immune cells. Conversely, high-purity, highly proliferative tumors will naturally have higher expression of cell-cycle genes. Statistical adjustment for tumor purity or single-cell validation is required.

### 3. Clinical confounding
No clinical covariates were provided. The reported HRs may be confounded by age, stage, grade, molecular subtype, or treatment exposure. For example, ER-positive luminal tumors often have lower proliferation and better OS; the protective signal could partly reflect subtype distribution.

### 4. Modest effect sizes and gene-level limitations
Individual HRs are modest (HR ≈ 0.79–1.26). Although statistically robust, the clinical utility of individual genes is unclear. Many genes may be correlated with the same underlying proliferation or immune programs, so the effective number of independent signals is smaller than the number of significant genes.

### 5. Broad or multifunctional pathway annotations
Some genes are highly multifunctional. GSK3B, for example, participates in Wnt signaling, metabolism, and cell survival, and its direction in cancer is context-dependent. Likewise, Hallmark EMT includes both protective and adverse biology; the protective ECM/stromal genes should not be equated with aggressive EMT without additional evidence. A few protective genes, such as ABCB1 or RPA2, are counterintuitive based on their known roles in drug resistance or DNA replication, and should be interpreted cautiously.

---

## Conclusion

The strongest conclusion from this dataset is that a coordinated proliferative/mitotic program and a translation/ribosome/proteostasis program are associated with worse overall survival in breast cancer, while immune-cell lineage markers and ECM/differentiation-related genes are associated with better survival. These findings are statistically robust and biologically coherent, but they remain association-level results. The most urgent next steps are to distinguish tumor-cell-intrinsic signals from tissue-composition effects and to validate the most promising modules functionally and in independent clinical cohorts.
